Arcturus Therapeutics announces a $50 million investment from Meiji Seika Pharma to advance mRNA technology and therapeutic development.
| Name | Arcturus Therapeutics Holdings Inc. |
|---|---|
| CIK | 0001768224 |
| Tickers | ARCT |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Accelerated filer<br>Smaller reporting company |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 000000000 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | 8589002660 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 1 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Arcturus Therapeutics announces a $50 million investment from Meiji Seika Pharma to advance mRNA technology and therapeutic development.
Amova Asset Management Americas, Inc. has reported a 5.9% stake in Arcturus Therapeutics, reflecting growing interest in the pharmaceutical sector.
Arcturus Therapeutics Holdings Inc. shares its Q3 financial results, showcasing advancements in its pharmaceutical development efforts.
Sumitomo Mitsui Trust Group and Amova Asset Management have filed an updated 13G/A, revealing a significant stake in Arcturus Therapeutics Holdings Inc.
419 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-18 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0001193125-26-467309 | 005-91046 | 261571695 | 34 | 8235 | |||
| 2026-11-16 | 8-K | e665891_8k-arct.htm | 1.01,3.02,7.01,9.01 | 0001193805-26-001485 | 001-38942 | 261555690 | 34 | 211030 | 1 | 1 |
| 2026-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001140361-26-043682 | 005-91046 | 261551289 | 34 | 10318 | |||
| 2026-11-05 | 10-Q | 10-Q | 0001193125-26-449901 | 001-38942 | 261527649 | 34 | 7937154 | 1 | 1 | |
| 2026-11-05 | 8-K | e665874_8k-arct.htm | 2.02,9.01 | 0001193805-26-001439 | 001-38942 | 261527185 | 34 | 264076 | 1 | 1 |
| 2026-10-29 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001214659-26-013368 | 005-91046 | 261497256 | 34 | 12195 | |||
| 2026-10-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001623632-26-001546 | 005-91046 | 261445453 | 34 | 46404 | |||
| 2026-09-23 | 8-K | e665798_8k-arct.htm | 7.01,9.01 | 0001193805-26-001277 | 001-38942 | 261401135 | 34 | 6922466 | 1 | 1 |
| 2026-08-25 | 8-K | e665725_8k-arct.htm | 7.01,9.01 | 0001193805-26-001130 | 001-38942 | 261312288 | 34 | 589469 | 1 | 1 |
| 2026-08-06 | 10-Q | 10-Q | 0001193125-26-338090 | 001-38942 | 261249422 | 34 | 8965351 | 1 | 1 | |
| 2026-08-06 | 8-K | e665679_8k-arct.htm | 2.02,9.01 | 0001193805-26-001039 | 001-38942 | 261248880 | 34 | 260430 | 1 | 1 |
| 2026-07-02 | 8-K | e665618_8k-arct.htm | 1.01,7.01,9.01 | 0001193805-26-000910 | 001-38942 | 261147692 | 34 | 209070 | 1 | 1 |
| 2026-06-15 | 4 | xslF345X06/e665584_4-holmes.xml | 0001193805-26-000829 | 5615 | ||||||
| 2026-06-15 | 4 | xslF345X06/e665583_4-farrell.xml | 0001193805-26-000828 | 5766 | ||||||
| 2026-06-15 | 4 | xslF345X06/e665582_4-barlow.xml | 0001193805-26-000827 | 5566 | ||||||
| 2026-06-15 | 4 | xslF345X06/e665581_4-markels.xml | 0001193805-26-000826 | 5635 | ||||||
| 2026-06-15 | 4 | xslF345X06/e66580_4-slaoui.xml | 0001193805-26-000825 | 5624 | ||||||
| 2026-06-15 | 4 | xslF345X06/e665579_4-marquet.xml | 0001193805-26-000824 | 5600 | ||||||
| 2026-06-15 | 4 | xslF345X06/e665578_4-jing.xml | 0001193805-26-000823 | 5625 | ||||||
| 2026-06-05 | 8-K | e665552_8k-arct.htm | 5.07 | 0001193805-26-000770 | 001-38942 | 261070321 | 34 | 202174 | 1 | 1 |
| 2026-05-07 | 4 | xslF345X06/e665445_4-mulroy.xml | 0001193805-26-000578 | 5884 | ||||||
| 2026-05-07 | 3 | xslF345X06/e665444_3-mulroy.xml | 0001193805-26-000577 | 17138 | ||||||
| 2026-05-07 | 10-Q | 10-Q | 0001193125-26-211943 | 001-38942 | 26953465 | 34 | 6322908 | 1 | 1 | |
| 2026-05-07 | 8-K | e665435_8k-arct.htm | 2.02,5.02,7.01,9.01 | 0001193805-26-000573 | 001-38942 | 26953226 | 34 | 355379 | 1 | 1 |
| 2026-05-07 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001104659-26-057041 | 005-91046 | 26952683 | 34 | 13929 | |||
| 2026-04-24 | DEF 14A | e665392_def14a-arct.htm | 0001193805-26-000507 | 001-38942 | 26893540 | 34 | 749839 | |||
| 2026-03-26 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000102909-26-000697 | 005-91046 | 26797922 | 34 | 7158 | |||
| 2026-03-03 | 10-K | 10-K | 0001193125-26-088391 | 001-38942 | 26715171 | 34 | 16353080 | 1 | 1 | |
| 2026-03-03 | 8-K | e665201_8k-arct.htm | 2.02,9.01 | 0001193805-26-000214 | 001-38942 | 26713950 | 34 | 271516 | 1 | 1 |
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-26-052923 | 005-91046 | 26636190 | 34 | 131696 | |||
| 2026-02-03 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-26-009576 | 005-91046 | 26590882 | 34 | 15871 | |||
| 2026-01-08 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001623632-26-000033 | 005-91046 | 26517494 | 34 | 46309 | |||
| 2025-12-30 | S-3 | e665045_s3-arct.htm | 0001193805-25-001797 | 333-292486 | 251614162 | 33 | 1000028 | 1 | 1 | |
| 2025-12-19 | 4 | xslF345X05/e665069_4-roberts.xml | 0001193805-25-001767 | 5697 | ||||||
| 2025-12-19 | 4 | xslF345X05/e665060_4-chivukula.xml | 0001193805-25-001766 | 5741 | ||||||
| 2025-12-19 | 4 | xslF345X05/e665059_4-payne.xml | 0001193805-25-001765 | 5725 | ||||||
| 2025-12-19 | 4 | xslF345X05/e665058_4-kurata.xml | 0001193805-25-001764 | 5721 | ||||||
| 2025-12-19 | 3 | xslF345X02/e665061_3-roberts.xml | 0001193805-25-001763 | 15837 | ||||||
| 2025-12-15 | 8-K | e665044_8k-arct.htm | 5.02,9.01 | 0001193805-25-001734 | 001-38942 | 251570105 | 34 | 338873 | 1 | 1 |
| 2025-11-14 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-281215 | 005-91046 | 251480806 | 34 | 130326 | |||
| 2025-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001140361-25-041835 | 005-91046 | 251475814 | 34 | 11134 | |||
| 2025-11-12 | 10-Q | 10-Q | 0001193125-25-275758 | 001-38942 | 251468445 | 34 | 7121445 | 1 | 1 | |
| 2025-11-12 | NT 10-Q | e664959_nt10q-arct.htm | 0001193805-25-001558 | 001-38942 | 251468022 | 34 | 18548 | |||
| 2025-11-10 | 8-K | e664953_8k-arct.htm | 2.02,9.01 | 0001193805-25-001555 | 001-38942 | 251466245 | 34 | 271250 | 1 | 1 |
| 2025-10-27 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-015320 | 005-91046 | 251417384 | 34 | 12570 | |||
| 2025-10-22 | 8-K | e664913_8k-arct.htm | 7.01,8.01,9.01 | 0001193805-25-001499 | 001-38942 | 251408612 | 34 | 2341998 | 1 | 1 |
| 2025-09-26 | 8-K | e664858_8k-arct.htm | 7.01,9.01 | 0001193805-25-001368 | 001-38942 | 251345338 | 34 | 298514 | 1 | 1 |
| 2025-08-29 | 8-K | e664805_8k-arct.htm | 7.01,9.01 | 0001193805-25-001247 | 001-38942 | 251275729 | 34 | 236608 | 1 | 1 |
| 2025-08-20 | 4/A | xslF345X05/e664797_4a-sassine.xml | 0001193805-25-001215 | 5179 | ||||||
| 2025-08-19 | 4 | xslF345X05/e664791_4-sassine.xml | 0001193805-25-001212 | 5101 | ||||||
| 2025-08-11 | 10-Q | 10-Q | 0000950170-25-106560 | 001-38942 | 251202168 | 34 | 6850773 | 1 | 1 | |
| 2025-08-11 | 8-K | e664773_8k-arct.htm | 2.02,9.01 | 0001193805-25-001175 | 001-38942 | 251201903 | 34 | 275511 | 1 | 1 |
| 2025-07-30 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001104659-25-072057 | 005-91046 | 251165781 | 34 | 14103 | |||
| 2025-07-29 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000932471-25-000838 | 005-91046 | 251159485 | 34 | 6272 | |||
| 2025-06-30 | 8-K | e664658_8k-arct.htm | 7.01,9.01 | 0001193805-25-000946 | 001-38942 | 251092031 | 34 | 8272070 | 1 | 1 |
| 2025-06-11 | 4 | xslF345X05/e664624_4-farrell.xml | 0001193805-25-000878 | 5717 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664623_4-slaoui.xml | 0001193805-25-000877 | 5576 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664622_4-marquet.xml | 0001193805-25-000876 | 5551 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664621_4-markels.xml | 0001193805-25-000875 | 5586 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664620_4-jing.xml | 0001193805-25-000874 | 5576 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664619_4-barlow.xml | 0001193805-25-000873 | 5517 | ||||||
| 2025-06-11 | 4 | xslF345X05/e664618_4-holmes.xml | 0001193805-25-000872 | 5566 | ||||||
| 2025-06-06 | 8-K | e664613_8k-arct.htm | 5.07 | 0001193805-25-000820 | 001-38942 | 251030606 | 34 | 212742 | 1 | 1 |
| 2025-05-12 | 10-Q | 10-Q | 0000950170-25-069210 | 001-38942 | 25934929 | 34 | 6053718 | 1 | 1 | |
| 2025-05-12 | 8-K | e664482_8k-arct.htm | 2.02,9.01 | 0001193805-25-000630 | 001-38942 | 25934735 | 34 | 294833 | 1 | 1 |
| 2025-05-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001140361-25-018349 | 005-91046 | 25934113 | 34 | 11721 | |||
| 2025-04-25 | DEF 14A | e664405_def14a-arct.htm | 0001193805-25-000561 | 001-38942 | 25875213 | 34 | 723714 | |||
| 2025-04-25 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001214659-25-006367 | 005-91046 | 25869783 | 34 | 11902 | |||
| 2025-04-23 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-001467 | 005-91046 | 25863196 | 34 | 11126 | |||
| 2025-03-06 | 10-K | 10-K | 0000950170-25-034787 | 001-38942 | 25715856 | 34 | 18088223 | 1 | 1 | |
| 2025-03-06 | 8-K | e664243_8k-arct.htm | 2.02,9.01 | 0001193805-25-000275 | 001-38942 | 25715122 | 34 | 321213 | 1 | 1 |
| 2025-02-05 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000093751-25-000091 | 005-91046 | 25590935 | 34 | 8090 | |||
| 2024-12-18 | 4 | xslF345X05/e664086_4-kurata.xml | 0001193805-24-001493 | 5816 | ||||||
| 2024-12-18 | 4 | xslF345X05/e664085_4-payne.xml | 0001193805-24-001492 | 5820 | ||||||
| 2024-12-18 | 4 | xslF345X05/e664084_4-chivukula.xml | 0001193805-24-001491 | 5836 | ||||||
| 2024-12-18 | 4 | xslF345X05/e664083_4-sassine.xml | 0001193805-24-001490 | 5789 | ||||||
| 2024-11-08 | SC 13G | SC 13G | 0001140361-24-045812 | 005-91046 | 241440120 | 34 | 69156 | |||
| 2024-11-07 | 10-Q | 10-Q | 0000950170-24-123469 | 001-38942 | 241436852 | 34 | 5908548 | 1 | 1 | |
| 2024-11-07 | 8-K | e663993_8k-arct.htm | 2.02,9.01 | 0001193805-24-001318 | 001-38942 | 241436238 | 34 | 286669 | 1 | 1 |
| 2024-11-05 | SC 13G | arct1027246sc13g.htm | 0001214659-24-018425 | 005-91046 | 241425444 | 34 | 62985 | |||
| 2024-10-16 | 4 | xslF345X05/e663956_4-chivukula.xml | 0001193805-24-001248 | 5429 | ||||||
| 2024-10-15 | 144 | xsl144X01/primary_doc.xml | 0001971857-24-000670 | 001-38942 | 241372163 | 33 | 4437 | |||
| 2024-08-13 | 8-K | e663829_8k-arct.htm | 7.01,9.01 | 0001193805-24-001023 | 001-38942 | 241198811 | 34 | 5577800 | 1 | 1 |
| 2024-08-05 | 10-Q | 10-Q | 0000950170-24-090905 | 001-38942 | 241175638 | 34 | 5918354 | 1 | 1 | |
| 2024-08-05 | 8-K | e663815_8k-arct.htm | 2.02,9.01 | 0001193805-24-000990 | 001-38942 | 241174821 | 34 | 305334 | 1 | 1 |
| 2024-07-17 | S-8 | e663719_s8-arct.htm | 0001193805-24-000937 | 333-280860 | 241123075 | 33 | 209335 | |||
| 2024-06-24 | 8-K | e663734_8k-arct.htm | 5.02,7.01,9.01 | 0001193805-24-000842 | 001-38942 | 241064346 | 34 | 219919 | 1 | 1 |
| 2024-06-21 | 4 | xslF345X05/e663735_4-jing.xml | 0001193805-24-000836 | 7938 | ||||||
| 2024-06-21 | 3 | xslF345X02/e663736_3-jing.xml | 0001193805-24-000835 | 3054 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663730_4-jing.xml | 0001193805-24-000829 | 9855 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663729_4-holmes.xml | 0001193805-24-000828 | 9845 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663728_4-markels.xml | 0001193805-24-000827 | 9865 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663727_4-marquet.xml | 0001193805-24-000826 | 10534 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663726_4-barlow.xml | 0001193805-24-000825 | 9797 | ||||||
| 2024-06-18 | 4 | xslF345X05/e663725_4-farrell.xml | 0001193805-24-000824 | 10697 | ||||||
| 2024-06-18 | 144 | xsl144X01/primary_doc.xml | 0001972362-24-000923 | 001-38942 | 241053226 | 33 | 8069 | |||
| 2024-06-14 | 8-K | e663711_8k-arct.htm | 5.02,5.07,9.01 | 0001193805-24-000806 | 001-38942 | 241045342 | 34 | 405746 | 1 | 1 |
| 2024-06-14 | 4 | xslF345X05/e663716_4-sassine.xml | 0001193805-24-000801 | 5385 | ||||||
| 2024-06-12 | 144 | xsl144X01/primary_doc.xml | 0001949846-24-000345 | 001-38942 | 241037654 | 33 | 4270 | |||
| 2024-06-07 | 4 | xslF345X05/e663692_4-chivukula.xml | 0001193805-24-000768 | 5316 | ||||||
| 2024-06-05 | 144 | xsl144X01/primary_doc.xml | 0001971857-24-000352 | 001-38942 | 241022754 | 33 | 6572 | |||
| 2024-06-04 | 4 | xslF345X05/e663681_4-chivukula.xml | 0001193805-24-000746 | 5425 | ||||||
| 2024-06-03 | 144 | xsl144X01/primary_doc.xml | 0001971857-24-000335 | 001-38942 | 241013006 | 33 | 5857 | |||
| 2024-05-08 | 10-Q | 10-Q | 0000950170-24-055702 | 001-38942 | 24926356 | 34 | 5809909 | 1 | 1 | |
| 2024-05-08 | 8-K | e663590_8k-arct.htm | 2.02,9.01 | 0001193805-24-000614 | 001-38942 | 24925804 | 34 | 304442 | 1 | 1 |
| 2024-04-29 | DEF 14A | e663528_def14a-arct.htm | 0001193805-24-000574 | 001-38942 | 24890603 | 34 | 911069 | |||
| 2024-04-05 | 8-K | e663496_8k-arct.htm | 4.01,9.01 | 0001193805-24-000505 | 001-38942 | 24827264 | 34 | 206136 | 1 | 1 |
| 2024-04-05 | SC 13G/A | us03969t1097_040424.txt | 0001086364-24-007344 | 005-91046 | 24825578 | 34 | 13774 | |||
| 2024-03-27 | 4 | xslF345X05/e663461_4-chivukula.xml | 0001193805-24-000452 | 5427 | ||||||
| 2024-03-21 | 4 | xslF345X05/e619136_4-chivukula.xml | 0001193805-24-000426 | 5424 | ||||||
| 2024-03-19 | 144 | xsl144X01/primary_doc.xml | 0002002698-24-000009 | 001-38942 | 24764080 | 33 | 4434 | |||
| 2024-03-19 | 8-K | e619378_8k-arct.htm | 7.01,9.01 | 0001193805-24-000392 | 001-38942 | 24760979 | 34 | 240267 | 1 | 1 |
| 2024-03-14 | 10-K | 10-K | 0000950170-24-031156 | 001-38942 | 24748092 | 34 | 18608954 | 1 | 1 | |
| 2024-03-14 | 8-K/A | e619365_8ka-arct.htm | 2.02,9.01 | 0001193805-24-000364 | 001-38942 | 24748083 | 34 | 206165 | 1 | 1 |
| 2024-03-07 | 8-K | e619328_8k-arct.htm | 2.02,9.01 | 0001193805-24-000335 | 001-38942 | 24730055 | 34 | 303172 | 1 | 1 |
| 2024-02-23 | 8-K | e619292_8k-arct.htm | 5.02,9.01 | 0001193805-24-000264 | 001-38942 | 24671126 | 34 | 193671 | 1 | 1 |
| 2024-02-13 | SC 13G/A | SCHEDULE 13G/A | 0001104659-24-020320 | 005-91046 | 24627479 | 34 | 13126 | |||
| 2024-02-12 | SC 13G/A | SC 13G/A | 0001140361-24-007096 | 005-91046 | 24621778 | 34 | 62763 | |||
| 2024-02-05 | SC 13G/A | AMENDMENT NO. 2 | 0001214659-24-001839 | 005-91046 | 24593846 | 34 | 64322 | |||
| 2024-01-29 | SC 13G/A | SC 13G/A | 0001104659-24-007711 | 005-91046 | 24573555 | 34 | 51871 | |||
| 2024-01-25 | SC 13G/A | us03969t1097_012524.txt | 0001086364-24-003240 | 005-91046 | 24561017 | 34 | 13778 | |||
| 2024-01-25 | SC 13G/A | ArcturusTherapeu.txt | 0000093751-24-000198 | 005-91046 | 24558599 | 34 | 8560 | |||
| 2024-01-17 | SC 13G/A | arct1567-form.htm | 0001623632-24-000025 | 005-91046 | 24538026 | 34 | 433059 | |||
| 2023-12-19 | 4 | xslF345X05/e619137_4-sassine.xml | 0001193805-23-001630 | 5789 | ||||||
| 2023-12-19 | 4 | xslF345X05/e619136_4-chivukula.xml | 0001193805-23-001629 | 5839 | ||||||
| 2023-12-19 | 4 | xslF345X05/e619135_4-kurata.xml | 0001193805-23-001628 | 5816 | ||||||
| 2023-12-19 | 4 | xslF345X05/e619134_4-kummerfeld.xml | 0001193805-23-001627 | 5912 | ||||||
| 2023-12-19 | 4 | xslF345X05/e619133_4-payne.xml | 0001193805-23-001626 | 5820 | ||||||
| 2023-11-14 | 10-Q | 10-Q | 0000950170-23-063778 | 001-38942 | 231407140 | 34 | 7071222 | 1 | 1 | |
| 2023-11-14 | 8-K | e619057_8k-arct.htm | 2.02,9.01 | 0001193805-23-001493 | 001-38942 | 231406214 | 34 | 316869 | 1 | 1 |
| 2023-11-03 | 4 | xslF345X05/e619041_4-chivukula.xml | 0001193805-23-001470 | 5345 | ||||||
| 2023-10-10 | SC 13G/A | Arcturus_Thera_Hold_Inc.txt | 0000093751-23-000683 | 005-91046 | 231316636 | 34 | 8474 | |||
| 2023-10-04 | 4 | xslF345X05/e618979_4-chivukula.xml | 0001193805-23-001361 | 5344 | ||||||
| 2023-10-02 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000719 | 001-38942 | 231299952 | 33 | 7195 | |||
| 2023-09-26 | 8-K | e618944_8k-arct.htm | 1.01,8.01,9.01 | 0001193805-23-001328 | 001-38942 | 231280538 | 34 | 215110 | 1 | 1 |
| 2023-09-05 | 4 | xslF345X05/e618918_4-chivukula.xml | 0001193805-23-001249 | 5346 | ||||||
| 2023-09-01 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000605 | 001-38942 | 231230939 | 33 | 7196 | |||
| 2023-08-17 | 4 | xslF345X05/e618886_4-sassine.xml | 0001193805-23-001195 | 5024 | ||||||
| 2023-08-14 | 8-K | e618874_8k-arct.htm | 1.01,8.01,9.01 | 0001193805-23-001174 | 001-38942 | 231169880 | 34 | 211356 | 1 | 1 |
| 2023-08-07 | 10-Q | 10-Q | 0000950170-23-039149 | 001-38942 | 231148352 | 34 | 7900540 | 1 | 1 | |
| 2023-08-07 | 8-K | e618839_8k-arct.htm | 2.02,8.01,9.01 | 0001193805-23-001112 | 001-38942 | 231147932 | 34 | 475700 | 1 | 1 |
| 2023-08-07 | 424B5 | e618843_424b5-arct.htm | 0001193805-23-001110 | 333-269003 | 231147901 | 33 | 13077 | |||
| 2023-08-03 | 4 | xslF345X05/e618822_4-chivukula.xml | 0001193805-23-001075 | 5341 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618812_4-markels.xml | 0001193805-23-001074 | 8542 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618811_4-farrell.xml | 0001193805-23-001073 | 8673 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618810_4-jing.xml | 0001193805-23-001072 | 8532 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618809_4-holmes.xml | 0001193805-23-001071 | 8521 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618808_4-barlow.xml | 0001193805-23-001070 | 8473 | ||||||
| 2023-08-03 | 4 | xslF345X05/e618807_4-marquet.xml | 0001193805-23-001069 | 8506 | ||||||
| 2023-08-01 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000458 | 001-38942 | 231130217 | 33 | 8615 | |||
| 2023-07-18 | 4 | xslF345X05/e618783_4-chivukula.xml | 0001193805-23-001003 | 5342 | ||||||
| 2023-07-18 | 4 | xslF345X05/e618788_4-kummerfeld.xml | 0001193805-23-001002 | 16399 | ||||||
| 2023-07-14 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-002344 | 001-38942 | 231089691 | 33 | 5370 | |||
| 2023-07-14 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000390 | 001-38942 | 231088980 | 33 | 8620 | |||
| 2023-07-14 | 8-K | e618777_8k-arct.htm | 7.01 | 0001193805-23-000984 | 001-38942 | 231088046 | 34 | 198862 | 1 | 1 |
| 2023-07-07 | 4 | xslF345X04/e618766_4-chivukula.xml | 0001193805-23-000955 | 5339 | ||||||
| 2023-06-30 | 8-K | e618740_8k-arct.htm | 7.01,9.01 | 0001193805-23-000929 | 001-38942 | 231059599 | 34 | 218402 | 1 | 1 |
| 2023-06-16 | 8-K | e618703_8k-arct.htm | 5.07 | 0001193805-23-000861 | 001-38942 | 231021727 | 34 | 206562 | 1 | 1 |
| 2023-06-05 | 4 | xslF345X04/e618686_4-chivukula.xml | 0001193805-23-000824 | 5338 | ||||||
| 2023-05-12 | 4 | xslF345X04/e618625_4-chivukula.xml | 0001193805-23-000719 | 7409 | ||||||
| 2023-05-11 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000095 | 001-38942 | 23911974 | 33 | 7195 | |||
| 2023-05-10 | 144 | xsl144X01/primary_doc.xml | 0001971857-23-000089 | 001-38942 | 23908465 | 33 | 6512 | |||
| 2023-05-09 | 10-Q | 10-Q | 0000950170-23-019773 | 001-38942 | 23902764 | 34 | 7977395 | 1 | 1 | |
| 2023-05-09 | 8-K | e618600_8k-arct.htm | 2.02,9.01 | 0001193805-23-000686 | 001-38942 | 23902099 | 34 | 275477 | 1 | 1 |
| 2023-05-03 | 4 | xslF345X04/e618570_4-chivukula.xml | 0001193805-23-000656 | 5333 | ||||||
| 2023-05-01 | DEF 14A | e618536_def14a-arct.htm | 0001193805-23-000633 | 001-38942 | 23874247 | 34 | 601648 | |||
| 2023-04-28 | 8-K | FORM 8-K | 7.01,9.01 | 0001193805-23-000619 | 001-38942 | 23859810 | 34 | 219078 | 1 | 1 |
| 2023-04-21 | 8-K | e618524_8k-arct.htm | 1.01,2.03,9.01 | 0001193805-23-000595 | 001-38942 | 23837334 | 34 | 197444 | 1 | 1 |
| 2023-04-19 | 4 | xslF345X04/e618515_4-kummerfeld.xml | 0001193805-23-000578 | 16483 | ||||||
| 2023-04-17 | 144 | xsl144X01/primary_doc.xml | 0001950047-23-000155 | 001-38942 | 23824930 | 33 | 4697 | |||
| 2023-04-11 | 8-K | e618488_8k-arct.htm | 7.01,9.01 | 0001193805-23-000532 | 001-38942 | 23812464 | 34 | 200233 | 1 | 1 |
| 2023-04-05 | 4 | xslF345X04/e618445_4-chivukula.xml | 0001193805-23-000516 | 5335 | ||||||
| 2023-03-29 | 10-K | 10-K | 0000950170-23-010380 | 001-38942 | 23771164 | 34 | 17477426 | 1 | 1 | |
| 2023-03-28 | 8-K | e618402_8k-arct.htm | 2.02,9.01 | 0001193805-23-000401 | 001-38942 | 23769628 | 34 | 299382 | 1 | 1 |
| 2023-03-17 | 8-K | e618370_8k-arct.htm | 1.02 | 0001193805-23-000356 | 001-38942 | 23742773 | 34 | 194573 | 1 | 1 |
| 2023-03-08 | 4 | xslF345X03/e618338_4-chivukula.xml | 0001193805-23-000295 | 5303 | ||||||
| 2023-02-10 | SC 13G/A | SC 13G/A | 0001104659-23-018109 | 005-91046 | 23609294 | 34 | 45006 | |||
| 2023-02-10 | SC 13G/A | SC 13G/A | 0001140361-23-005791 | 005-91046 | 23609168 | 34 | 68700 | |||
| 2023-02-09 | SC 13G | SCHEDULE 13G | 0001104659-23-015345 | 005-91046 | 23602456 | 34 | 13016 | |||
| 2023-02-08 | SC 13G/A | Arcturus_Thera_Hold_Inc.txt | 0000093751-23-000343 | 005-91046 | 23597405 | 34 | 10371 | |||
| 2023-02-03 | SC 13G/A | AMENDMENT NO. 1 | 0001214659-23-001559 | 005-91046 | 23583646 | 34 | 63246 | |||
| 2023-02-01 | SC 13G/A | form817.htm | 0001623632-23-000210 | 005-91046 | 23575092 | 34 | 212961 | |||
| 2023-01-31 | SC 13G/A | us03969t1097_013123.txt | 0001306550-23-005189 | 005-91046 | 23571845 | 34 | 13441 | |||
| 2022-12-30 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2022-12-30 17:00:00 | 9999999995-23-000017 | 333-269003 | 23500004 | 33 | 1749 | ||
| 2022-12-30 | CORRESP | filename1.htm | 0001193805-22-001808 | 7323 | ||||||
| 2022-12-29 | UPLOAD | filename1.pdf | 0000000000-22-014003 | 40282 | ||||||
| 2022-12-27 | DEL AM | e618160_delam-arct.htm | 0001193805-22-001791 | 333-269003 | 221491123 | 33 | 6425 | |||
| 2022-12-23 | S-3 | e618047_s3-at.htm | 0001193805-22-001786 | 333-269003 | 221485990 | 33 | 1114683 | |||
| 2022-12-19 | 4 | xslF345X03/e618133_4-marquet.xml | 0001193805-22-001748 | 4679 | ||||||
| 2022-12-16 | 4 | xslF345X03/e618136_4-kummerfeld.xml | 0001193805-22-001746 | 5872 | ||||||
| 2022-12-13 | 8-K | e618121_8k-arct.htm | 5.02,7.01,9.01 | 0001193805-22-001719 | 001-38942 | 221459874 | 34 | 214111 | 1 | 1 |
| 2022-12-13 | 4 | xslF345X03/e618117_4-markels.xml | 0001193805-22-001718 | 7933 | ||||||
| 2022-12-13 | 3 | xslF345X02/e618110_3-markels.xml | 0001193805-22-001717 | 3011 | ||||||
| 2022-12-13 | 4 | xslF345X03/e618109_4-sassine.xml | 0001193805-22-001716 | 5765 | ||||||
| 2022-12-13 | 4 | xslF345X03/e618108_4-payne.xml | 0001193805-22-001715 | 5793 | ||||||
| 2022-12-13 | 4 | xslF345X03/e618107_4-chivukula.xml | 0001193805-22-001714 | 5812 | ||||||
| 2022-12-13 | 4 | xslF345X03/e618106_4-kurata.xml | 0001193805-22-001713 | 5792 | ||||||
| 2022-12-13 | 8-K | e618105_8k-arct.htm | 7.01,9.01 | 0001193805-22-001712 | 001-38942 | 221458593 | 34 | 199309 | 1 | 1 |
| 2022-11-28 | 4 | xslF345X03/e618061_4-payne.xml | 0001193805-22-001614 | 4792 | ||||||
| 2022-11-09 | 10-Q | 10-Q | 0000950170-22-023969 | 001-38942 | 221373454 | 34 | 10866158 | 1 | 1 | |
| 2022-11-09 | 8-K | e618005_8k-arct.htm | 2.02,9.01 | 0001193805-22-001504 | 001-38942 | 221372539 | 34 | 282754 | 1 | 1 |
| 2022-11-04 | 8-K | FORM 8-K | 1.01,1.02,9.01 | 0001193805-22-001480 | 001-38942 | 221362962 | 34 | 324406 | 1 | 1 |
| 2022-11-02 | 8-K | e617985_8k-arct.htm | 1.01,9.01 | 0001193805-22-001470 | 001-38942 | 221351824 | 34 | 225208 | 1 | 1 |
| 2022-09-01 | 8-K | e621904_8k-arct.htm | 1.01,9.01 | 0001193805-22-001230 | 001-38942 | 221221687 | 34 | 214317 | 1 | 1 |
| 2022-08-17 | 4 | xslF345X03/e621887_4-sassine.xml | 0001193805-22-001207 | 4993 | ||||||
| 2022-08-09 | 10-Q | 10-Q | 0000950170-22-016043 | 001-38942 | 221148323 | 34 | 7270513 | 1 | 1 | |
| 2022-08-09 | 8-K | e621864_8k-arct.htm | 2.02,9.01 | 0001193805-22-001152 | 001-38942 | 221148079 | 34 | 285749 | 1 | 1 |
| 2022-06-30 | S-8 | e621786_s8-arct.htm | 0001193805-22-001036 | 333-265925 | 221058077 | 33 | 216379 | |||
| 2022-06-27 | 4 | xslF345X03/e621785_4-farrell.xml | 0001193805-22-001024 | 5534 | ||||||
| 2022-06-27 | 4 | xslF345X03/e621784_4-marquet.xml | 0001193805-22-001023 | 5368 | ||||||
| 2022-06-27 | 4 | xslF345X03/e621783_4-jing.xml | 0001193805-22-001022 | 5381 | ||||||
| 2022-06-27 | 4 | xslF345X03/e621782_4-barlow.xml | 0001193805-22-001021 | 5334 | ||||||
| 2022-06-27 | 4 | xslF345X03/e621781_4-holmes.xml | 0001193805-22-001020 | 5383 | ||||||
| 2022-06-24 | 8-K | e621778_8k-arct.htm | 1.01,5.07,9.01 | 0001193805-22-001014 | 001-38942 | 221040978 | 34 | 420192 | 1 | 1 |
| 2022-06-23 | 4 | xslF345X03/e621776_4-kummerfeld.xml | 0001193805-22-001003 | 6052 | ||||||
| 2022-06-23 | 4 | xslF345X03/e621773_4-chivukula.xml | 0001193805-22-001002 | 5989 | ||||||
| 2022-06-23 | 4 | xslF345X03/e621772_4-payne.xml | 0001193805-22-001001 | 5973 | ||||||
| 2022-06-23 | 4 | xslF345X03/e621771_4-sassine.xml | 0001193805-22-001000 | 5942 | ||||||
| 2022-06-23 | 4 | xslF345X03/e621770_4-kurata.xml | 0001193805-22-000999 | 5954 | ||||||
| 2022-05-12 | DEFR14A | e621618_defr14a-arct.htm | 0001193805-22-000778 | 001-38942 | 22918786 | 34 | 762508 | |||
| 2022-05-09 | 10-Q | 10-Q | 0000950170-22-008524 | 001-38942 | 22905538 | 34 | 6422427 | 1 | 1 | |
| 2022-05-09 | 8-K | e621634_8k-arct.htm | 2.02,9.01 | 0001193805-22-000752 | 001-38942 | 22905300 | 34 | 302781 | 1 | 1 |
| 2022-05-02 | DEF 14A | e621607_def14a-arct.htm | 0001193805-22-000731 | 001-38942 | 22883307 | 34 | 760806 | |||
| 2022-04-20 | 8-K | e621578_8k-arct.htm | 1.01,1.02,8.01,9.01 | 0001193805-22-000672 | 001-38942 | 22839060 | 34 | 233206 | 1 | 1 |
| 2022-04-11 | SC 13G/A | Arcturus_Therapeutics.txt | 0000093751-22-000487 | 005-91046 | 22819296 | 34 | 10404 | |||
| 2022-03-01 | 10-K | 10-K | 0001564590-22-007832 | 001-38942 | 22693445 | 34 | 22173701 | 1 | 1 | |
| 2022-02-28 | 8-K | e621394_8k-arct.htm | 2.02,9.01 | 0001193805-22-000402 | 001-38942 | 22689760 | 34 | 287286 | 1 | 1 |
| 2022-02-17 | 8-K | e621367_8k-arct.htm | 8.01,9.01 | 0001193805-22-000358 | 001-38942 | 22645670 | 34 | 8820141 | 1 | 1 |
| 2022-02-15 | SC 13G | e621353_sc13g-vpi.htm | 0001193805-22-000325 | 35281 | ||||||
| 2022-02-14 | SC 13G/A | arct13gadec21.txt | 0000080255-22-002218 | 005-91046 | 34 | 7074 | ||||
| 2022-02-14 | SC 13G | form37.htm | 0001623632-22-000216 | 005-91046 | 22628540 | 34 | 278185 | |||
| 2022-02-14 | SC 13G | SC13G | 0001140361-22-005022 | 005-91046 | 22624439 | 34 | 63433 | |||
| 2022-02-11 | 8-K | e621318_8k-arct.htm | 5.02 | 0001193805-22-000265 | 001-38942 | 22622363 | 34 | 192400 | 1 | 1 |
| 2022-02-11 | SC 13G | ARCTURUS_THERAPEUTICS_.txt | 0000093751-22-000236 | 005-91046 | 22617167 | 34 | 10360 | |||
| 2022-02-09 | SC 13G/A | SC 13G/A | 0001104659-22-016106 | 005-91046 | 22605761 | 34 | 41095 | |||
| 2022-02-04 | SC 13G | arct21224sc13g.htm | 0001214659-22-001836 | 005-91046 | 22590810 | 34 | 63130 | |||
| 2022-02-03 | SC 13G/A | us03969t1097_020322.txt | 0000834237-22-006390 | 005-91046 | 22589150 | 34 | 13465 | |||
| 2022-01-11 | 8-K | e621207_8k-arct.htm | 7.01 | 0001193805-22-000036 | 001-38942 | 22522722 | 34 | 196994 | 1 | 1 |
| 2022-01-06 | 4 | xslF345X03/e621194_4-chivukula.xml | 0001193805-22-000015 | 4756 | ||||||
| 2021-12-20 | 4 | xslF345X03/e621144_4-chivukula.xml | 0001193805-21-001784 | 4759 | ||||||
| 2021-12-13 | 8-K | e621155_8k-at.htm | 5.02,5.05,7.01,9.01 | 0001193805-21-001738 | 001-38942 | 211488884 | 34 | 345733 | 1 | 1 |
| 2021-12-10 | 4 | xslF345X03/e621144_4-chivukula.xml | 0001193805-21-001726 | 4757 | ||||||
| 2021-12-09 | 4 | xslF345X03/e621146_4-jing.xml | 0001193805-21-001718 | 7883 | ||||||
| 2021-12-09 | 3 | xslF345X02/e621145_3-jing.xml | 0001193805-21-001717 | 2961 | ||||||
| 2021-11-16 | 8-K | e621084_8k-at.htm | 8.01,9.01 | 0001193805-21-001584 | 001-38942 | 211416260 | 34 | 7854563 | 1 | 1 |
| 2021-11-09 | SC 13G/A | SCHEDULE 13G/A | 0001104659-21-136120 | 005-91046 | 211390929 | 34 | 52354 | |||
| 2021-11-09 | 10-Q | ARCT Q3 20210930 | 0001564590-21-055372 | 001-38942 | 211389389 | 34 | 8103076 | 1 | 1 | |
| 2021-11-08 | 8-K | e621064_8k-at.htm | 2.02,9.01 | 0001193805-21-001541 | 001-38942 | 211388224 | 34 | 293082 | 1 | 1 |
| 2021-11-03 | 4 | xslF345X03/e621049_4-chivukula.xml | 0001193805-21-001522 | 5312 | ||||||
| 2021-11-01 | 8-K | e621046_8k-at.htm | 1.01,9.01 | 0001193805-21-001517 | 001-38942 | 211367634 | 34 | 194211 | 1 | 1 |
| 2021-10-26 | SC 13D/A | SC 13D/A | 0001193125-21-308036 | 005-91046 | 211349171 | 34 | 43425 | |||
| 2021-10-20 | S-8 | e621018_s8-arct.htm | 0001193805-21-001468 | 333-260391 | 211334957 | 33 | 214700 | |||
| 2021-10-05 | 8-K | e620993_8k-at.htm | 1.01,2.03 | 0001193805-21-001417 | 001-38942 | 211307538 | 34 | 195111 | 1 | 1 |
| 2021-10-04 | 4 | xslF345X03/e620990_4-chivukula.xml | 0001193805-21-001408 | 5311 | ||||||
| 2021-09-02 | 4 | xslF345X03/e620921_4-chivukula.xml | 0001193805-21-001272 | 5313 | ||||||
| 2021-08-26 | 8-K | e620900_8k-arct.htm | 1.02,5.02 | 0001193805-21-001224 | 001-38942 | 211212528 | 34 | 195162 | 1 | 1 |
| 2021-08-12 | 4 | FORM 4 SUBMISSION | 0001209191-21-051182 | 7269 | ||||||
| 2021-08-12 | SC 13D/A | SC 13D/A | 0001193125-21-244861 | 005-91046 | 211168626 | 34 | 43345 | |||
| 2021-08-10 | NT 10-Q | e620856_nt10q-arct.htm | 0001193805-21-001143 | 001-38942 | 211158174 | 34 | 18266 | |||
| 2021-08-10 | 10-Q | ARCT Q2 20210630 | 0001564590-21-042750 | 001-38942 | 211157673 | 34 | 7650654 | 1 | 1 | |
| 2021-08-09 | 8-K | e620853_8k-arct.htm | 2.02,7.01,9.01 | 0001193805-21-001134 | 001-38942 | 211156370 | 34 | 9276519 | 1 | 1 |
| 2021-08-05 | 4 | xslF345X03/e620845_4-chivukula.xml | 0001193805-21-001112 | 5310 | ||||||
| 2021-08-04 | 8-K | e620837_8k-at.htm | 1.01 | 0001193805-21-001100 | 001-38942 | 211144207 | 34 | 198909 | 1 | 1 |
| 2021-06-22 | 4 | xslF345X03/e620749_4-parschauer.xml | 0001193805-21-000929 | 5358 | ||||||
| 2021-06-22 | 4 | xslF345X03/e620748_4-marquet.xml | 0001193805-21-000928 | 5365 | ||||||
| 2021-06-22 | 4 | xslF345X03/e620747_4-holmes.xml | 0001193805-21-000927 | 5380 | ||||||
| 2021-06-22 | 4 | xslF345X03/e620746_4-barlow.xml | 0001193805-21-000926 | 5331 | ||||||
| 2021-06-22 | 4 | xslF345X03/e620745_4-farrell.xml | 0001193805-21-000925 | 5531 | ||||||
| 2021-06-22 | 8-K | e620743_8k-at.htm | 5.07 | 0001193805-21-000923 | 001-38942 | 211035708 | 34 | 203791 | 1 | 1 |
| 2021-05-10 | 10-Q | ARCT 10-Q 20210331 | 0001564590-21-026113 | 001-38942 | 21908114 | 34 | 5139982 | 1 | 1 | |
| 2021-05-10 | 8-K | e620580_8k-arct.htm | 2.02,7.01,9.01 | 0001193805-21-000630 | 001-38942 | 21907527 | 34 | 8298770 | 1 | 1 |
| 2021-04-30 | DEF 14A | e620530_def14a-arct.htm | 0001193805-21-000583 | 001-38942 | 21877654 | 34 | 612316 | |||
| 2021-04-26 | 8-K | e620514_8k-arct.htm | 5.02,9.01 | 0001193805-21-000538 | 001-38942 | 21854943 | 34 | 264557 | 1 | 1 |
| 2021-04-05 | 4 | xslF345X03/e620448_4-chivukula.xml | 0001193805-21-000455 | 5308 | ||||||
| 2021-03-03 | 4 | xslF345X03/e620351_4-chivukula.xml | 0001193805-21-000323 | 5308 | ||||||
| 2021-03-01 | 8-K | e620337_8k-arct.htm | 2.02,7.01,9.01 | 0001193805-21-000289 | 001-38942 | 21698049 | 34 | 8381304 | 1 | 1 |
| 2021-03-01 | 10-K | ARCT 10-K 20201231 | 0001564590-21-009872 | 001-38942 | 21698006 | 34 | 11123812 | 1 | 1 | |
| 2021-02-22 | 8-K | e620313_8k-arct.htm | 3.02,8.01,9.01 | 0001193805-21-000256 | 001-38942 | 21661148 | 34 | 209581 | 1 | 1 |
| 2021-02-16 | SC 13G/A | SC 13G/A | 0001104659-21-024172 | 005-91046 | 21639382 | 34 | 44791 | |||
| 2021-02-16 | SC 13G/A | sched13g.htm | 0000929638-21-000368 | 005-91046 | 21636790 | 34 | 85631 | |||
| 2021-02-16 | SC 13G | arct13gdec20.txt | 0000080255-21-001330 | 005-91046 | 34 | 6876 | ||||
| 2021-02-12 | SC 13G/A | SC 13G/A | 0001104659-21-021915 | 005-91046 | 21627341 | 34 | 210962 | |||
| 2021-02-10 | 3 | xslF345X02/e620263_3-arct.xml | 0001193805-21-000156 | 001-40034 | 21609391 | 34 | 4298 | |||
| 2021-02-03 | 4 | xslF345X03/e620251_4-chivukula.xml | 0001193805-21-000124 | 5311 | ||||||
| 2021-02-03 | 8-K | FORM 8-K- | 2.03 | 0001193805-21-000122 | 001-38942 | 21585340 | 34 | 197363 | 1 | 1 |
| 2021-02-02 | SC 13G | us03969t1097_020221.txt | 0000834237-21-007117 | 005-91046 | 21580871 | 34 | 13369 | |||
| 2021-01-08 | SC 13G | form.htm | 0001623632-21-000003 | 005-91046 | 21516917 | 34 | 438006 | |||
| 2021-01-05 | 4 | xslF345X03/e620192_4-chivukula.xml | 0001193805-21-000014 | 5310 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620165_4-kummerfeld.xml | 0001193805-20-001611 | 5468 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620164_4-chivukula.xml | 0001193805-20-001610 | 5417 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620163_4-payne.xml | 0001193805-20-001609 | 5389 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620162_4-sassine.xml | 0001193805-20-001608 | 6188 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620161_4-hughes.xml | 0001193805-20-001607 | 5375 | ||||||
| 2020-12-22 | 4 | xslF345X03/e620160_4-kurata.xml | 0001193805-20-001606 | 5379 | ||||||
| 2020-12-10 | 4 | FORM 4 SUBMISSION | 0001209191-20-062733 | 7303 | ||||||
| 2020-12-10 | SC 13D/A | SC 13D/A | 0001193125-20-314963 | 005-91046 | 201381196 | 34 | 40753 | |||
| 2020-12-08 | 424B5 | e620129_424b5-at.htm | 0001193805-20-001522 | 333-251175 | 201376195 | 33 | 440877 | |||
| 2020-12-08 | 8-K | e620125_8k-at.htm | 1.01,7.01,9.01 | 0001193805-20-001508 | 001-38942 | 201374488 | 34 | 9165338 | 1 | 1 |
| 2020-12-07 | 424B5 | e620118_424b5-at.htm | 0001193805-20-001505 | 333-251175 | 201373529 | 33 | 438862 | |||
| 2020-12-07 | S-3ASR | e620120_s3asr-at.htm | 0001193805-20-001500 | 333-251175 | 201372896 | 33 | 700381 | |||
| 2020-12-07 | 8-K | e620119_8k-at.htm | 1.01,9.01 | 0001193805-20-001498 | 001-38942 | 201371242 | 34 | 225838 | 1 | 1 |
| 2020-12-03 | 4 | xslF345X03/e620114_4-chivukula.xml | 0001193805-20-001491 | 5317 | ||||||
| 2020-11-25 | 8-K | e620104_8k-at.htm | 5.03,9.01 | 0001193805-20-001470 | 001-38942 | 201351353 | 34 | 203100 | 1 | 1 |
| 2020-11-13 | 8-K | e620078_8k-at.htm | 5.07,9.01 | 0001193805-20-001417 | 001-38942 | 201308606 | 34 | 195830 | 1 | 1 |
| 2020-11-09 | 10-Q | Q3 2020 10-Q | 0001564590-20-052527 | 001-38942 | 201297990 | 34 | 5692745 | 1 | ||
| 2020-11-09 | 8-K | e620071_8k-at.htm | 2.02,9.01 | 0001193805-20-001406 | 001-38942 | 201297703 | 34 | 273758 | 1 | 1 |
| 2020-11-03 | 4 | FORM 4 SUBMISSION | 0000899243-20-030320 | 5455 | ||||||
| 2020-10-15 | 8-K | e6120001_8k-at.htm | 8.01,9.01 | 0001193805-20-001274 | 001-38942 | 201240282 | 34 | 195028 | 1 | 1 |
| 2020-10-13 | DEF 14A | e619993_def14a-arct.htm | 0001193805-20-001272 | 001-38942 | 201236425 | 34 | 152937 | |||
| 2020-10-09 | SC 13G/A | SC 13G/A | 0001104659-20-113789 | 005-91046 | 201232771 | 34 | 46633 | |||
| 2020-10-02 | 4 | FORM 4 SUBMISSION | 0000899243-20-026884 | 5454 | ||||||
| 2020-10-02 | PRE 14A | e619969_pre14a-arct.htm | 0001193805-20-001230 | 001-38942 | 201220274 | 34 | 137045 | |||
| 2020-10-02 | 8-K | e619976_8k-at.htm | 8.01,9.01 | 0001193805-20-001229 | 001-38942 | 201220175 | 34 | 195781 | 1 | 1 |
| 2020-09-11 | SC 13G | SC 13G | 0001104659-20-104394 | 005-91046 | 201170918 | 34 | 165551 | |||
| 2020-09-04 | 4 | FORM 4 SUBMISSION | 0000899243-20-024363 | 5494 | ||||||
| 2020-08-18 | 8-K | e619881_8k-at.htm | 1.01,7.01,9.01 | 0001193805-20-001052 | 001-38942 | 201113582 | 34 | 218240 | 1 | 1 |
| 2020-08-12 | 4 | xslF345X03/e619870_4-kurata.xml | 0001193805-20-001022 | 5349 | ||||||
| 2020-08-12 | 3 | xslF345X02/e619869_3-kurata.xml | 0001193805-20-001021 | 11353 | ||||||
| 2020-08-10 | 10-Q | 10-Q 20200630 | 0001564590-20-038980 | 001-38942 | 201090130 | 34 | 5023365 | 1 | ||
| 2020-08-10 | 8-K | e619846_8k-at.htm | 2.02,9.01 | 0001193805-20-000987 | 001-38942 | 201089672 | 34 | 74725 | ||
| 2020-08-05 | S-8 | e619825_s8-at.htm | 0001193805-20-000940 | 333-240397 | 201074618 | 33 | 205833 | |||
| 2020-08-05 | S-8 | e619826_s8-at.htm | 0001193805-20-000939 | 333-240392 | 201074567 | 33 | 175945 | |||
| 2020-07-30 | 424B5 | e619812_424b5-at.htm | 0001193805-20-000907 | 333-238139 | 201059008 | 33 | 413365 | |||
| 2020-07-29 | 8-K | e619811_8k-at.htm | 1.01,9.01 | 0001193805-20-000902 | 001-38942 | 201055606 | 34 | 334425 | ||
| 2020-07-28 | 424B5 | e619809_424b5-at.htm | 0001193805-20-000900 | 333-238139 | 201054052 | 33 | 410661 | |||
| 2020-07-24 | 8-K | e619804_8k-at.htm | 8.01,9.01 | 0001193805-20-000886 | 001-38942 | 201044975 | 34 | 30711 | ||
| 2020-06-26 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-06-26 16:00:00 | 9999999995-20-001665 | 333-235475 | 201017185 | 33 | 1750 | ||
| 2020-06-24 | 4 | xslF345X03/e619725_4-parschauer.xml | 0001193805-20-000746 | 5281 | ||||||
| 2020-06-24 | 4 | xslF345X03/e619724_4-marquet.xml | 0001193805-20-000745 | 5288 | ||||||
| 2020-06-24 | 4 | xslF345X03/e619723_4-holmes.xml | 0001193805-20-000744 | 5303 | ||||||
| 2020-06-24 | 4 | xslF345X03/e619722_4-barlow.xml | 0001193805-20-000743 | 5254 | ||||||
| 2020-06-24 | 4 | xslF345X03/e619721_4-farrell.xml | 0001193805-20-000742 | 5454 | ||||||
| 2020-06-19 | CORRESP | filename1.htm | 0001193805-20-000721 | 7332 | ||||||
| 2020-06-18 | 8-K | e619707_8k-at.htm | 7.01,9.01 | 0001193805-20-000704 | 001-38942 | 20971903 | 34 | 2460354 | ||
| 2020-06-12 | 4 | FORM 4 SUBMISSION | 0000899243-20-016410 | 4639 | ||||||
| 2020-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-20-016050 | 4733 | ||||||
| 2020-06-10 | 4 | FORM 4 SUBMISSION | 0000899243-20-016049 | 4561 | ||||||
| 2020-06-09 | 8-K | 8-K | 5.07 | 0001193125-20-164097 | 001-38942 | 20950828 | 34 | 32902 | ||
| 2020-05-22 | SC 13D/A | SC 13D/A | 0001193125-20-150308 | 005-91046 | 20907120 | 34 | 57766 | |||
| 2020-05-22 | S-3/A | e619657_s3a-at.htm | 0001193805-20-000627 | 333-235475 | 20907074 | 33 | 165263 | |||
| 2020-05-22 | 4 | FORM 4 SUBMISSION | 0001209191-20-031641 | 6931 | ||||||
| 2020-05-21 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2020-05-21 16:00:00 | 9999999995-20-001236 | 333-238139 | 20903529 | 33 | 1749 | ||
| 2020-05-21 | 8-K | e619655_8k-at.htm | 3.02,7.01,9.01 | 0001193805-20-000622 | 001-38942 | 20902336 | 34 | 32061 | ||
| 2020-05-18 | CORRESP | filename1.htm | 0001193805-20-000600 | 7441 | ||||||
| 2020-05-15 | UPLOAD | filename1.pdf | 0000000000-20-004351 | 40206 | ||||||
| 2020-05-08 | S-3 | e619613_s3-at.htm | 0001193805-20-000569 | 333-238139 | 20861820 | 33 | 815086 | |||
| 2020-05-08 | 10-Q | 10-Q Q1 2020 | 0001564590-20-023633 | 001-38942 | 20861463 | 34 | 4103543 | 1 | ||
| 2020-05-07 | 8-K | e619610_8k-at.htm | 2.02,9.01 | 0001193805-20-000565 | 001-38942 | 20856364 | 34 | 69677 | ||
| 2020-04-29 | DEF 14A | e619589_def14a-arct.htm | 0001193805-20-000535 | 001-38942 | 20831072 | 34 | 678427 | |||
| 2020-04-27 | SC 13G | sched13g.htm | 0000929638-20-000538 | 005-91046 | 20819980 | 34 | 90563 | |||
| 2020-04-21 | 8-K | 8-K | 8.01 | 0001564590-20-017549 | 001-38942 | 20803889 | 34 | 33968 | ||
| 2020-04-17 | 424B5 | e619560_424b5-at.htm | 0001193805-20-000494 | 333-232281 | 20799680 | 33 | 348572 | |||
| 2020-04-17 | 8-K | 8-K | 1.01,1.02,8.01,9.01 | 0001564590-20-017147 | 001-38942 | 20797611 | 34 | 378298 | ||
| 2020-04-16 | S-3MEF | e619559_s3mef-at.htm | 0001193805-20-000491 | 333-237703 | 20795110 | 33 | 73050 | |||
| 2020-04-15 | 424B5 | e619556_424b5-at.htm | 0001193805-20-000486 | 333-232281 | 20793844 | 33 | 345903 | |||
| 2020-03-27 | 8-K | e619507_8k-at.htm | 1.01,9.01 | 0001193805-20-000412 | 001-38942 | 20752944 | 34 | 271811 | ||
| 2020-03-27 | 424B5 | e619508_424b5-at.htm | 0001193805-20-000411 | 333-232281 | 20752938 | 33 | 313877 | |||
| 2020-03-16 | 10-K | ARCT 10-K 20191231 | 0001564590-20-011037 | 001-38942 | 20715874 | 34 | 8528884 | 1 | ||
| 2020-03-11 | 8-K | e619458_8k-at.htm | 2.02,9.01 | 0001193805-20-000335 | 001-38942 | 20705280 | 34 | 68397 | ||
| 2020-03-04 | 8-K | e619429_8k-at.htm | 1.01 | 0001193805-20-000295 | 001-38942 | 20685799 | 34 | 34480 | ||
| 2020-02-24 | SEC STAFF LETTER | filename1.pdf | 9999999997-20-000993 | 226536 | ||||||
| 2020-02-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-005389 | 5461 | ||||||
| 2020-02-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-005387 | 5503 | ||||||
| 2020-02-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-005386 | 5430 | ||||||
| 2020-02-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-005383 | 5421 | ||||||
| 2020-02-20 | 3 | FORM 3 SUBMISSION | 0000899243-20-005382 | 2985 | ||||||
| 2020-02-20 | 4 | FORM 4 SUBMISSION | 0000899243-20-005379 | 5454 | ||||||
| 2020-02-03 | SEC STAFF LETTER | filename1.pdf | 9999999997-20-000424 | 230871 | ||||||
| 2020-01-10 | 8-K | e619284_8k-at.htm | 7.01,9.01 | 0001193805-20-000030 | 001-38942 | 20521396 | 34 | 5176122 | ||
| 2019-12-16 | UPLOAD | filename1.pdf | 0000000000-19-016451 | 46088 | ||||||
| 2019-12-12 | S-3 | S-3 | 0001193125-19-312823 | 333-235475 | 191282451 | 33 | 219048 | |||
| 2019-12-09 | 4 | FORM 4 SUBMISSION | 0000899243-19-028803 | 5072 | ||||||
| 2019-12-05 | 4 | FORM 4 SUBMISSION | 0000899243-19-028631 | 4568 | ||||||
| 2019-11-08 | 10-Q | 10-Q | 0001564590-19-042017 | 001-38942 | 191202142 | 34 | 5380893 | 1 | ||
| 2019-11-07 | 8-K | 8-K | 2.02,9.01 | 0001193125-19-287407 | 001-38942 | 191201110 | 34 | 82510 | ||
| 2019-11-07 | 8-K | 8-K | 7.01,9.01 | 0001193125-19-287260 | 001-38942 | 191200168 | 34 | 10324236 | ||
| 2019-10-31 | 8-K | 8-K | 1.01,5.07 | 0001193125-19-280541 | 001-38942 | 191184215 | 34 | 40177 | ||
| 2019-10-29 | 4 | FORM 4 SUBMISSION | 0000899243-19-026165 | 9614 | ||||||
| 2019-10-29 | 4 | FORM 4 SUBMISSION | 0000899243-19-026159 | 7592 | ||||||
| 2019-10-29 | 4 | FORM 4 SUBMISSION | 0000899243-19-026123 | 7618 | ||||||
| 2019-10-29 | 4 | FORM 4 SUBMISSION | 0000899243-19-026116 | 5302 | ||||||
| 2019-10-29 | 4 | FORM 4 SUBMISSION | 0000899243-19-026109 | 5468 | ||||||
| 2019-10-01 | DEF 14A | DEF 14A | 0001193125-19-259220 | 001-38942 | 191127532 | 34 | 1230923 | |||
| 2019-09-27 | 8-K | 8-K | 1.01,7.01,9.01 | 0001193125-19-257389 | 001-38942 | 191122378 | 34 | 251105 | ||
| 2019-09-27 | 424B5 | 424B5 | 0001193125-19-257362 | 333-232281 | 191122264 | 33 | 368539 | |||
| 2019-09-24 | 3 | FORM 3 SUBMISSION | 0000899243-19-024193 | 7352 | ||||||
| 2019-09-23 | 8-K | 8-K | 5.02,8.01,9.01 | 0001193125-19-252227 | 001-38942 | 191108394 | 34 | 33444 | ||
| 2019-09-17 | 4 | FORM 4 SUBMISSION | 0000899243-19-023769 | 8973 | ||||||
| 2019-09-16 | 8-K | 8-K | 8.01 | 0001193125-19-245891 | 001-38942 | 191095195 | 34 | 18195 | ||
| 2019-09-12 | 4 | FORM 4 SUBMISSION | 0000899243-19-023531 | 8972 | ||||||
| 2019-08-30 | 4 | FORM 4 SUBMISSION | 0000899243-19-022619 | 9313 | ||||||
| 2019-08-26 | 4 | FORM 4 SUBMISSION | 0000899243-19-022418 | 9616 | ||||||
| 2019-08-21 | 4 | FORM 4 SUBMISSION | 0000899243-19-022258 | 11806 | ||||||
| 2019-08-15 | 8-K | FORM 8-K | 7.01,9.01 | 0001193125-19-221871 | 001-38942 | 191028532 | 34 | 89943 | ||
| 2019-08-14 | 10-Q | 10-Q | 0001564590-19-032166 | 001-38942 | 191027197 | 34 | 6075056 | 1 | ||
| 2019-08-05 | 8-K | FORM 8-K | 1.01,7.01,9.01 | 0001193125-19-212594 | 001-38942 | 19997706 | 34 | 205940 | ||
| 2019-08-05 | 424B5 | 424B5 | 0001193125-19-212590 | 333-232281 | 19997699 | 33 | 367369 | |||
| 2019-08-02 | 8-K | 8-K | 1.01,7.01,9.01 | 0001193125-19-212082 | 001-38942 | 19996379 | 34 | 269078 | ||
| 2019-08-02 | 424B5 | 424B5 | 0001193125-19-212073 | 333-232281 | 19996361 | 33 | 365851 | |||
| 2019-08-01 | 8-K | e618580_8k-at.htm | 1.01,8.01,9.01 | 0001193805-19-000694 | 001-38942 | 19991828 | 34 | 29523 |
One latest value per concept from companyfacts (201 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 28.82M | 2026-11-03 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 323.50M | 2025-06-30 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 5.77M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AccountsReceivableNetCurrent | Accounts Receivable, after Allowance for Credit Loss, Current | USD | 1.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 22.16M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 13.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AdditionalPaidInCapital | Additional Paid in Capital | USD | 741.45M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 4.04M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 12.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | AllowanceForDoubtfulAccountsReceivable | Accounts Receivable, Allowance for Credit Loss | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 100,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | Assets | Assets | USD | 215.32M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 189.40M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | AssetsDisposedOfByMethodOtherThanSaleInPeriodOfDispositionGainLossOnDisposition1 | Assets Disposed of by Method Other than Sale, in Period of Disposition, Gain (Loss) on Disposition | USD | 0 | 2025-07-01 | 2025-09-30 | 2025 | Q3 | 10-Q | 2025-11-12 | 0001193125-25-275758 |
| us-gaap | CapitalExpendituresIncurredButNotYetPaid | Capital Expenditures Incurred but Not yet Paid | USD | 68,000 | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 184.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 186.84M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -45.95M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | CommonStockCapitalSharesReservedForFutureIssuance | Common Stock, Capital Shares Reserved for Future Issuance | shares | 5.53M | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-09 | 0001564590-20-052527 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0.001 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 60.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 28.46M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 28.46M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 28,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -58.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ContractualObligation | Contractual Obligation | USD | 3.49M | 2023-09-30 | 2023 | Q3 | 10-Q | 2023-11-14 | 0000950170-23-063778 | |
| us-gaap | ContractWithCustomerAssetNet | Contract with Customer, Asset, after Allowance for Credit Loss | USD | 1.25M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | ContractWithCustomerLiability | Contract with Customer, Liability | USD | 419,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized | USD | 803,000 | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 |
| us-gaap | ContractWithCustomerLiabilityRevenueRecognized | Contract with Customer, Liability, Revenue Recognized | USD | -23.32M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | CumulativeEffectOnRetainedEarningsTax1 | Cumulative Effect on Retained Earnings, Tax (Deprecated 2020-01-31) | USD | -803,000 | 2019-01-01 | 2019-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001564590-20-023633 |
| us-gaap | CurrentFederalTaxExpenseBenefit | Current Federal Tax Expense (Benefit) | USD | -11,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | CurrentIncomeTaxExpenseBenefit | Current Income Tax Expense (Benefit) | USD | -4,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | CurrentStateAndLocalTaxExpenseBenefit | Current State and Local Tax Expense (Benefit) | USD | 7,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | CustomerRefundLiabilityCurrent | Customer Refund Liability, Current | USD | 2.26M | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | DeferredIncomeTaxLiabilities | Deferred Tax Liabilities, Gross | USD | 5.17M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredRentCreditNoncurrent | Deferred Rent Credit, Noncurrent | USD | 534,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | DeferredRevenueCurrent | Deferred Revenue, Current | USD | 419,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | DeferredRevenueNoncurrent | Deferred Revenue, Noncurrent | USD | 12.60M | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsDeferredIncome | Deferred Tax Assets, Deferred Income | USD | 2.81M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsEquityMethodInvestments | Deferred Tax Assets, Equity Method Investments | USD | 2.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 148.69M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsInventory | Deferred Tax Assets, Inventory | USD | 15.96M | 2023-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 38.57M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwards | Deferred Tax Assets, Tax Credit Carryforwards | USD | 30.22M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 15.23M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | USD | 689,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 143.53M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | DepositLiabilityCurrent | Deposit Liability, Current | USD | 10.00M | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-10 | 0001564590-21-042750 | |
| us-gaap | DepreciationAndAmortization | Depreciation, Depletion and Amortization, Nonproduction | USD | 1.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | Dividends | Dividends | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -2.05 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -1.94 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008524 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -2.05 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.361 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate | Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent | pure | -0.014 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential | Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent | pure | 0.003 | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent | pure | 0.029 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent | pure | -0.019 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | -0.002 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings | Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Percent | pure | 0.285 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.019 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsOther | Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent | pure | 0.002 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | EmployeeRelatedLiabilitiesCurrent | Employee-related Liabilities, Current | USD | 8.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 30.10M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | EquityMethodInvestmentAggregateCost | Equity Method Investment, Aggregate Cost | USD | 9.20M | 2022-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 | |
| us-gaap | EquityMethodInvestmentOwnershipPercentage | Equity Method Investment, Ownership Percentage | pure | 0.3 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | EquityMethodInvestments | Equity Method Investments | USD | 515,000 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 | |
| us-gaap | ForeignCurrencyTransactionGainLossBeforeTax | Foreign Currency Transaction Gain (Loss), before Tax | USD | 382,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ForeignCurrencyTransactionGainLossRealized | Foreign Currency Transaction Gain (Loss), Realized | USD | 2,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | GainLossOnSaleOfPropertyPlantEquipment | Gain (Loss) on Disposition of Property Plant Equipment | USD | 52,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | GainsLossesOnExtinguishmentOfDebt | Gain (Loss) on Extinguishment of Debt | USD | 33.95M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 30.94M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | GoodwillImpairmentLoss | Goodwill, Impairment Loss | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic | Income (Loss) from Continuing Operations before Income Taxes, Domestic | USD | -65.78M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | USD | -58.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign | Income (Loss) from Continuing Operations before Income Taxes, Foreign | USD | -69,000 | 2019-01-01 | 2019-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | USD | 81.05M | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 |
| us-gaap | IncomeLossFromEquityMethodInvestments | Income (Loss) from Equity Method Investments | USD | -515,000 | 2022-01-01 | 2022-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 |
| us-gaap | IncomeTaxesPaidNet | Income Taxes Paid, Net | USD | 1.41M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInAccountsPayable | Increase (Decrease) in Accounts Payable | USD | 1.53M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInAccountsReceivable | Increase (Decrease) in Accounts Receivable | USD | -4.32M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInAccruedLiabilities | Increase (Decrease) in Accrued Liabilities | USD | -1.74M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInContractWithCustomerLiability | Increase (Decrease) in Contract with Customer, Liability | USD | -7.83M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInOperatingLeaseLiability | IncreaseDecreaseInOperatingLeaseLiability | USD | -2.54M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | -1.64M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | InterestExpenseLongTermDebt | Interest Expense, Long-term Debt | USD | 900,000 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 |
| us-gaap | InterestPaidNet | Interest Paid, Excluding Capitalized Interest, Operating Activities | USD | 2.13M | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 25.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 7.76M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 4.13M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 4.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 4.05M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 3.94M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 3.82M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 1.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 3.17M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | Liabilities | Liabilities | USD | 46.59M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 215.32M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 28.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 13.30M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023969 | |
| us-gaap | LongTermDebtCurrent | Long-term Debt, Current Maturities | USD | 60.66M | 2022-12-31 | 2023 | FY | 10-K | 2024-03-14 | 0000950170-24-031156 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths | Long-Term Debt, Maturity, Year One | USD | 10.30M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023969 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour | Long-Term Debt, Maturity, Year Four | USD | 6.70M | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-10 | 0001564590-20-038980 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree | Long-Term Debt, Maturity, Year Three | USD | 6.55M | 2020-12-31 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo | Long-Term Debt, Maturity, Year Two | USD | 8.63M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 | |
| us-gaap | LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear | Long-Term Debt, Maturity, Remainder of Fiscal Year | USD | 3.00M | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-09 | 0000950170-22-023969 | |
| us-gaap | LongTermDebtNoncurrent | Long-term Debt, Excluding Current Maturities | USD | 15.00M | 2025-03-31 | 2025 | Q1 | 10-Q | 2025-05-12 | 0000950170-25-069210 | |
| us-gaap | LossContingencyDamagesSoughtValue | Loss Contingency, Damages Sought, Value | USD | 30.00M | 2020-01-17 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 307,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -46.26M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -58.16M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segment | 1 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 86.98M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -63.66M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 2.80M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | OperatingLeaseImpairmentLoss | Operating Lease, Impairment Loss | USD | 1.90M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 21.86M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 3.62M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 18.24M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 19.09M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.046 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 560,000 | 2019-09-30 | 2019 | Q3 | 10-Q | 2019-11-08 | 0001564590-19-042017 | |
| us-gaap | OtherAssetsCurrent | Other Assets, Current | USD | 593,000 | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001564590-20-023633 | |
| us-gaap | OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | 3,000 | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 497,000 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | OtherNoncashIncomeExpense | Other Noncash Income (Expense) | USD | -502,000 | 2023-01-01 | 2023-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | OtherNonoperatingIncomeExpense | Other Nonoperating Income (Expense) | USD | -26,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | PaymentsToAcquireInterestInJointVenture | Payments to Acquire Interest in Joint Venture | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 52,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | PaymentsToAcquireShortTermInvestments | Payments to Acquire Short-term Investments | USD | 6.59M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 |
| us-gaap | PrepaidExpenseCurrent | Prepaid Expense, Current | USD | 1.34M | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-08 | 0001564590-20-023633 | |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 11.69M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ProceedsFromIssuanceOfDebt | Proceeds from Issuance of Debt | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ProceedsFromIssuanceOfLongTermDebt | Proceeds from Issuance of Long-term Debt | USD | 46.60M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 |
| us-gaap | ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised | USD | 15.54M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 |
| us-gaap | ProceedsFromIssuanceOrSaleOfEquity | Proceeds from Issuance or Sale of Equity | USD | 21.40M | 2019-07-01 | 2019-09-30 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 |
| us-gaap | ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments | Proceeds from Maturities, Prepayments and Calls of Short-term Investments | USD | 30.21M | 2018-01-01 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 |
| us-gaap | ProceedsFromSaleOfMachineryAndEquipment | Proceeds from Sale of Machinery and Equipment | USD | 52,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 66,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ProceedsFromStockPlans | Proceeds from Stock Plans | USD | 241,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 18.29M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 4.81M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | RepaymentsOfDebt | Repayments of Debt | USD | 0 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 56.04M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ResearchAndDevelopmentInProcess | Research and Development in Process | USD | 5.00M | 2021-01-01 | 2021-12-31 | 2022 | FY | 10-K | 2023-03-29 | 0000950170-23-010380 |
| us-gaap | RestrictedCash | Restricted Cash | USD | 55.00M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | RestrictedCashCurrent | Restricted Cash, Current | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | RestrictedCashNoncurrent | Restricted Cash, Noncurrent | USD | 2.03M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -572.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | RevenueFromContractWithCustomerExcludingAssessedTax | Revenue from Contract with Customer, Excluding Assessed Tax | USD | 23.32M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | USD | 2.74M | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | SegmentReportingOtherItemAmount | SegmentReportingOtherItemAmount | USD | -5.50M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 12.60M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | shares | 18,786 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | USD/shares | 34.92 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 8.65M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 6.05M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 33.12 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 500,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares | 1.14M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 2.03M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 3.89 | 2019-01-01 | 2019-06-30 | 2019 | Q2 | 10-Q | 2019-08-14 | 0001564590-19-032166 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 13.33M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 8.87M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 29.2 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | USD | 9.25M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | shares | 8.08M | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | USD/shares | 32.38 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | USD | 29.30M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 10.72 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | USD/shares | 33.9 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 11.37 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | SharePrice | Share Price | USD/shares | 34.92 | 2023-08-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 168.73M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 1 | 2019-06-12 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 103,440 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 5.00M | 2021-01-01 | 2021-12-31 | 2023 | FY | 10-K | 2024-03-14 | 0000950170-24-031156 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 11.69M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | USD | 15.54M | 2019-01-01 | 2019-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 50,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | TaxesPayableCurrent | Taxes Payable, Current | USD | 641,000 | 2023-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | TreasuryStockCommonShares | Treasury Stock, Common, Shares | shares | 43,000 | 2018-12-31 | 2019 | FY | 10-K | 2020-03-16 | 0001564590-20-011037 | |
| us-gaap | UnbilledReceivablesCurrent | Unbilled Receivables, Current | USD | 3.61M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 6.94M | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 | |
| us-gaap | UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities | Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-01 | 0001564590-22-007832 |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 925,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions | USD | 300,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-01 | 0001564590-21-009872 |
| us-gaap | UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate | Unrecognized Tax Benefits that Would Impact Effective Tax Rate | USD | 0 | 2024-12-31 | 2024 | FY | 10-K | 2025-03-06 | 0000950170-25-034787 | |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 5.50M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-03-03 | 0001193125-26-088391 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 28.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 26.38M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008524 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 28.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-05 | 0001193125-26-449901 |